Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and safety of ipilimumab has not been evaluated in Asian melanoma patients with a high frequency of mucosal and acral melanoma subtypes. Materials and Methods Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter named-patient program (NPP) were evaluated between September 2014 and July 2015. Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio (NLR) were assessed, and outcome and adverse events were evaluated according to subtypes. Results A total of 104 advanced melanoma patients were treated. The primary sites were acral (31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight patients (65.4%) experienced adverse events, and the most common toxicity was skin rash (22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85), and there was no difference in PFS according to subtypes. Poor performance status, liver metastasis, and NLR ( 5) were independent poor prognostic factors by multivariate analysis. Conclusion In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR.
Abstract
Purpose Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and safety of ipilimumab has not been evaluated in Asian melanoma patients with a high frequency of mucosal and acral melanoma subtypes. Materials and Methods Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter named-patient program (NPP) were evaluated between September 2014 and July 2015. Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio (NLR) were assessed, and outcome and adverse events were evaluated according to subtypes. Results A total of 104 advanced melanoma patients were treated. The primary sites were acral (31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight patients (65.4%) experienced adverse events, and the most common toxicity was skin rash (22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85), and there was no difference in PFS according to subtypes. Poor performance status, liver metastasis, and NLR ( 5) were independent poor prognostic factors by multivariate analysis. Conclusion In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR.
참고문헌 (25)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Dummer R, "Cutaneous melanoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v126~v132 (2015)
- Ascierto PA, "Clinical experience with ipilimumab 3mg", kg : real-world efficacy and safety data from an expanded access programme cohort, 2014, pp.12, 116~
- Tsao H, "Management of cutaneous melanoma", N Engl J Med, 351, pp.998~1012 (2004)
- Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
- Chapman PB, "Improved survival with vemurafenib in melanoma with BRAF V600E mutation", N Engl J Med, 364, pp.2507~2516 (2011)
- Schadendorf D, "Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma", J Clin Oncol, 33, pp.1889~1894 (2015)
- Ahmad SS, "Ipilimumab in the real world : the UK expanded access programme experience in previously treated advanced melanoma patients", Melanoma Res, 25, pp.432~442 (2015)
- Ishihara K, "Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update", Int J Clin Oncol, 13, pp.33~41 (2008)
- 장홍선, "Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure", Annals of Dermatology, 26(4), pp.485~490 (2014), 대한피부과학회
- Chi Z, "Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese : a study of 522 consecutive cases", BMC Cancer, 11, pp.85~ (2011)
- Chang JW, "Malignant melanoma in Taiwan : a prognostic study of 181 cases", Melanoma Res, 14, pp.537~541 (2004)
- Balch CM, "Final version of 2009 AJCC melanoma staging and classification", J Clin Oncol, 27, pp.6199~6206 (2009)
- Kelderman S, "Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma", Cancer Immunol Immunother, 63, pp.449~458 (2014)
- Berrocal A, "Ipilimumab for advanced melanoma : experience from the Spanish Expanded Access Program", Melanoma Res, 24, pp.577~583 (2014)
- Cormier JN, "Ethnic differences among patients with cutaneous melanoma", Arch Intern Med, 166, pp.1907~1914 (2006)
- Wu XC, "Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006", J Am Acad Dermatol, 65(5 Suppl 1), pp.S26~S37 (2011)
- Seetharamu N, "Mucosal melanomas : a case-based review of the literature", Oncologist, 15, pp.772~781 (2010)
- Del Vecchio M, "Efficacy and safety of ipilimumab 3mg", kg in patients with pretreated, metastatic, mucosal melanoma, 2014, pp.50, 121~127
- Yamazaki N, "Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma", Cancer Chemother Pharmacol, 76, pp.997~1004 (2015)
- Wu CF, "Ipilimumab in treating Asian patient with advanced melanoma:the preliminary report of Taiwan ipilimumab extended access program group", J Clin Oncol, 33(Suppl) (2015)
- Ferrucci PF, "Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients", Br J Cancer, 112, pp.1904~1910 (2015)
- Delyon J, "Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma : an early increase in lymphocyte and eosinophil counts is associated with improved survival", Ann Oncol, 24, pp.1697~1703 (2013)
- Queirolo P, "Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases", J Neurooncol, 118, pp.109~116 (2014)
- Weber JS, "Management of immunerelated adverse events and kinetics of response with ipilimumab", J Clin Oncol, 30, pp.2691~2697 (2012)